Tybourne is a global investment firm with a fundamental approach to equity investing, both public and private
Business Model:
Revenue: $0
Employees: 0-0
Address: 2 Queen's Road Central
City: Hong kong
State: other
Zip:
Country: HK
Tybourne provides asset management and investment advisory services.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
2/2015 | FreeCharge | Series C | 80M |
12/2018 | Bicycle Therapeutics | Series B | 27.9M |
1/2021 | Momo | Series D | 0 |
11/2022 | Clove Dental | Series D | 67M |
10/2020 | LianBio | Series A | 0 |
5/2020 | Zentera Therapeutics | Series A | 20M |
1/2019 | CarDekho | Series C | 110M |
3/2021 | Paidy | Series D | 0 |
7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
8/2021 | Zentera Therapeutics | Series B | 75M |
9/2022 | ACELYRIN | Series C | 0 |
11/2021 | ACELYRIN | Series B | 0 |
1/2015 | GirnarSoft | Series B | 50M |
8/2021 | CADDi | Series B | 0 |
11/2021 | Lunit | Venture Round | 0 |
10/2019 | Provivi | Series C | 0 |
9/2022 | Asuene | Series B | 17.5M |
1/2015 | CarDekho | Series B | 50M |
5/2014 | Snapdeal | Series E | 100M |
11/2019 | Paidy | Series C | 83M |
12/2020 | Provivi | Series C | 0 |
7/2021 | Wugen | Series B | 0 |
12/2021 | Kopi Kenangan | Series C | 0 |
12/2021 | Kopi Kenangan | Series C | 0 |
11/2021 | Lunit | Venture Round | 0 |
11/2021 | ACELYRIN | Series B | 0 |
8/2021 | CADDi | Series B | 0 |
8/2021 | Zentera Therapeutics | Series B | 0 |
7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
7/2021 | Wugen | Series B | 0 |
3/2021 | Paidy | Series D | 0 |
1/2021 | Momo | Series D | 0 |
12/2020 | Provivi | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|